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878-2 Oral Rapamycin in Patients Undergoing Coronary Stent 
Therapy: Final Results of the ORAR Study (Oral 
Rapamycin in Argentina)
Alfredo E. Rodriguez, Máximo Rodriguez Alemparte, Carlos Fernandez Pereira, César F. 
Vigo, Claudio LLauradó, Miguel Russo Felsen, Antonio Pocovi, David Vetcher, Otamendi 
Hospital, Buenos Aires, Argentina, Argentine Society for Cardiac Intervention, Buenos 
Aires, Argentina
Background:We previously reported (ACC03) preliminary findings of this study suggest-
ing that high concentration of rapamycin blood level (>8ng/ml) is associated with a trend
to low late loss and restenosis rate in patients(pts) undergoing coronary stent therapy.
Methods:From December 2001 to February 2003, 76 pts with 103 arteries treated with
stents were included in phase I (34 pts/49 arteries) and phase II (42 pts/54 arteries) of
the ORAR study. A loading dosis of 6 mg of oral rapamycin was administered inmediately
after stent deployment in all pts. In Phase I, 2 mg of oral rapamycin was given daily dur-
ing 28 days. In Phase II 3 mg daily of rapamycin was given plus 160 mg of diltiazem dur-
ing 28 days. Rapamycin blood levels were measured at third week in all pts.Cholesterol
and triglycerides were evaluated before and after one month of treatment. Statins were
given as well clopidogrel in all pts during six months. Angiographic binary restenosis, late
loss, target lesion revascularization, treatment compliance,side effects and optimal con-
centration of the drug were analized. At the present time 6 month angiographic follow up
data were available in 82.5% of the arteries.
Results:Baseline clinical characteristics showed diabetes 25.2%, type B1, B2 and C
lesions in 81%, reference vessel size <2.9 mm in 37% and with a lesion lenght of 11.1 +
0.8 mm. Minor side effects were present in 25% of the patients but only three discontinue
the treatment (4%). Follow up quantitative angiographic data showed that pts having > 8
ng/ml compared with those having < 8 ng /ml had lower late loss ( 0.65 mm vs. 1.11 mm
respectively p < 0.031), binary in stent restenosis (6.2% vs.23% respectively p < 0.039)
and better MLD ( 2.16 mm vs.1.71 respectively p< 0.054) . Pearson test showed strong
correlation between blood level of the drug and late loss ( r<0.001) Minor adverse side
effects had a trend to increased with high blood concentration of the drug (p=0.083).
Conclusions: Oral rapamycin after coronary stent deployment in those pts who reached
high concentration of the drug are associated with low late loss, binary restenosis and
better MLD in the follow up angiogram. A randomized drug / placebo study is ongoing
(ORAR II).
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878-3 Subgroup Analysis of the Impact of the Glycoprotein IIb/
IIIa Inhibitor Abciximab in Patients Undergoing Elective 
Stent Placement >2 Hours After Treatment With a 600 
Milligram Loading Dose of Clopidogrel: Results From 
the ISAR REACT Trial
Peter B. Berger, Adnan Kastrati, Julinda Mehilli, Helmut Schuhlen, Josef Dirschinger, 
Franz Dotzer, Jurrien M. ten Berg, Franz-Josef Neumann, Hildegard Bollwein, Christian 
Volmer, Meinrad Gawaz, Albert Schomig, Mayo Clinic, Rochester, MN, Deutsches 
Herzzentrum Munchen, Munich, Germany
ISAR REACT was designed to evaluate whether the glycoprotein IIb/IIIa inhibitor abcix-
imab is beneficial in low and intermediate risk patients undergoing elective percutaneous
coronary intervention (PCI) with a stent after maximal inhibition of aggregation had been
achieved after pretreatment with a high, 600 mg loading dose of clopidogrel. The fre-
quency of events among subgroups, including the 20% of pts with non-insulin dependent
diabetes (n=441), has not been reported. (See figure for results)
Conclusion: In these subgroups of varying risk among the low to intermediate risk
patients who undergo elective PCI after pretreatment with a high loading dose of clopi-
dogrel >2 hours prior to elective PCI, the results suggest that, as in the entire trial glyco-
protein IIb/IIIa inhibitor abciximab is associated with no clinically measurable benefit
within the first 30 days.
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878-4 Qualitative and Quantitative Analysis of Saphenous 
Vein Graft Plaque Debris Within the MedNova 
CardioShield™ Embolic Capture Device
David R. Holmes, Jr., on behalf of the CAPTIVE Pivotal Study Investigators, Deena 
Weber, Frank Kolodgie, Renu Virmani, Mayo Clinic, Rochester, MN, Armed Forces 
Institute of Pathology, Washington, DC
Background: There is limited information on the composition of atheroembolic debris
released during stent treatment of diseased aorto-coronary bypass saphenous vein
grafts (SVG). Intravascular filtration systems provide a unique opportunity to analyze
plaque debris captured following SVG intervention.
Device Description: The CardioShield embolic capture device consists of a polyurethane
membrane having 140 micron distal perfusion holes, two proximal entry ports, and an
internal self-expanding nitinol support system. The filter is delivered over a pre-placed
0.014” filter delivery wire, allowing independent wire movement, and is deployed distal to
the SVG target lesion. Following stenting, the filter is removed using a retrieval catheter
system.
Methods: One-hundred sixteen (116) filter devices utilized during stent treatment of 113
SVG lesions were submitted for histologic and morphometric analysis. Filter contents
were removed, embedded, and microscopically evaluated to establish a profile of the
contained embolic debris.
Results: Atheroembolic debris was collected in 95 (82%) of the 116 devices. In the
devices containing debris, 72 (76%) demonstrated macrophage foam cells, 46 (48%) had
smooth muscle cells, and 85 (90%) had necrotic core. Other identified debris included
platelets/fibrin in 89 (94%), cholesterol clefts in 56 (59%), and collagen/elastin in 51
(54%). Use of a platelet glycoprotein IIb/IIIa inhibitor did not affect a difference in fre-
quency, amount or composition of embolic debris. Morphometric measurements on
1,193 particles yielded an average particle size of 0.11 mm2 and minimal/maximal areas
of 0.02 mm2 and 0.50 mm2, respectively. The area of the largest particle was 3.47 mm2.
The majority of devices contained particles _ 0.1 mm2.
Conclusions: During treatment of SVG disease, embolic debris is frequently liberated and
seen in the majority of patients. The debris typically consists of necrotic core, macroph-
age foam cells, and platelet/fibrin aggregates. This filter system is effective at capturing
released embolic particles of variable size and composition.
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878-5 Provisional Versus Systematic T Stenting: Insights 
From a Large Prospective Single-Center Database
André Kokis, Gunasekaran Sengottuvel, Thierry Lefèvre, Samer Mansour, Yves Louvard, 
Pierre Dumas, Christophe Loubeyre, Marie-Claude Morice, Institut Cardiovasculaire 
Paris Sud, Massy, France
Background: Although numerous studies on PCI in bifurcation lesions are available, the
superiority of either provisional or systematic T stenting has not been conclusively
proven. Our registry is a large, single centre database on patients undergoing PCI in cor-
onary bifurcations and will give insights on this issue .
Methods. Our registry of PCI in bifurcation lesions started in November 1995 including
patients who undergo treatment for true and false bifurcation lesions. We compared from
this prospective database the in-hospital and 6 months outcome following systematic ver-
sus provisional T stenting for bifurcation lesions.
Results: Of the 1149 patients, provisional T stenting strategy was the most commonly
adopted strategy with 837 patients. In the provisional T-stenting group, 25.6 % patients
also required a stent in the side branch. 297 received systematic T stenting which was
performed using Type A treatment (Systematic T stenting of the side branch first) in 8.3
%, Type C treatment (Culotte) in 1.9 % and Type D treatment (V stenting) in 6 %. Base-
line characteristics were similar in both groups. The angiographic success (residual
stenosis < 50 %) was 93.6 % vs 91.8% in the main branch and 90.6 % vs 84.6% in the
side branch in the systematic versus provisional T stenting group. In the provisional T
stenting group compared to systematic T stenting group all measured parameters were
significantly lower: in-hospital MACE (3.2% vs 7.4%, p = 0.008), in- hospital death (0.1%
vs 1.3%, p = 0.02), sub-acute thrombosis (0.1 % vs 1.7 %, p = 0.007), need for urgent
CRP IL-6 IL-1RA sCD40L
Pre-PCI 9.4±14 6.9±10 545±378 0.80±0.46
10 Minutes Post PCI 8.9±13 7.81±11 594±421 1.08±0.86
P Value 0.82 0.60 0.45 0.01
